https://stock.noler.com/us/stock/eidos-therapeutics-inc https://stock.noler.com/us/stock/eidos-therapeutics-inc/accounts-payable https://stock.noler.com/us/stock/eidos-therapeutics-inc/accrued-liabilities-current-and-noncurrent https://stock.noler.com/us/stock/eidos-therapeutics-inc/accumulated-depreciation https://stock.noler.com/us/stock/eidos-therapeutics-inc/additional-paid-in-capital https://stock.noler.com/us/stock/eidos-therapeutics-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/eidos-therapeutics-inc/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/eidos-therapeutics-inc/amortization-of-financing-costs-and-discounts https://stock.noler.com/us/stock/eidos-therapeutics-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/eidos-therapeutics-inc/assets-fair-value-disclosure https://stock.noler.com/us/stock/eidos-therapeutics-inc/basic-shares https://stock.noler.com/us/stock/eidos-therapeutics-inc/capital-expenditures https://stock.noler.com/us/stock/eidos-therapeutics-inc/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/eidos-therapeutics-inc/cash-and-equivalents https://stock.noler.com/us/stock/eidos-therapeutics-inc/cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/eidos-therapeutics-inc/cash-flow-breakdown https://stock.noler.com/us/stock/eidos-therapeutics-inc/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/eidos-therapeutics-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/eidos-therapeutics-inc/common-stock-value https://stock.noler.com/us/stock/eidos-therapeutics-inc/comprehensive-income https://stock.noler.com/us/stock/eidos-therapeutics-inc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/eidos-therapeutics-inc/conversion-of-stock-amount-converted https://stock.noler.com/us/stock/eidos-therapeutics-inc/convertible-preferred-stock-shares-issued-upon-conversion https://stock.noler.com/us/stock/eidos-therapeutics-inc/cost-of-revenue https://stock.noler.com/us/stock/eidos-therapeutics-inc/costs-and-expenses https://stock.noler.com/us/stock/eidos-therapeutics-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/eidos-therapeutics-inc/current-assets https://stock.noler.com/us/stock/eidos-therapeutics-inc/current-liabilities https://stock.noler.com/us/stock/eidos-therapeutics-inc/debt-carrying-amount https://stock.noler.com/us/stock/eidos-therapeutics-inc/debt-issued https://stock.noler.com/us/stock/eidos-therapeutics-inc/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/eidos-therapeutics-inc/debt-maturing-in-year-four https://stock.noler.com/us/stock/eidos-therapeutics-inc/debt-maturing-in-year-three https://stock.noler.com/us/stock/eidos-therapeutics-inc/debt-maturing-in-year-two https://stock.noler.com/us/stock/eidos-therapeutics-inc/debt-maturing-remainder-of-fiscal-year https://stock.noler.com/us/stock/eidos-therapeutics-inc/debt-unamortized-discount-premium-and-debt-issuance-costs-net https://stock.noler.com/us/stock/eidos-therapeutics-inc/deferred-compensation-share-based-arrangements-liability-current https://stock.noler.com/us/stock/eidos-therapeutics-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/eidos-therapeutics-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/eidos-therapeutics-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/eidos-therapeutics-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/eidos-therapeutics-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/eidos-therapeutics-inc/deferred-tax-assets-tax-credit-carryforwards-research https://stock.noler.com/us/stock/eidos-therapeutics-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/eidos-therapeutics-inc/depreciation https://stock.noler.com/us/stock/eidos-therapeutics-inc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/eidos-therapeutics-inc/derivative-liabilities-noncurrent https://stock.noler.com/us/stock/eidos-therapeutics-inc/diluted-shares https://stock.noler.com/us/stock/eidos-therapeutics-inc/dilutive-shares https://stock.noler.com/us/stock/eidos-therapeutics-inc/due-from-related-parties-current https://stock.noler.com/us/stock/eidos-therapeutics-inc/due-to-related-parties-current https://stock.noler.com/us/stock/eidos-therapeutics-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/eidos-therapeutics-inc/effective-tax-rate https://stock.noler.com/us/stock/eidos-therapeutics-inc/embedded-derivative-gain-loss-on-embedded-derivative-net https://stock.noler.com/us/stock/eidos-therapeutics-inc/employee-related-liabilities-current https://stock.noler.com/us/stock/eidos-therapeutics-inc/eps https://stock.noler.com/us/stock/eidos-therapeutics-inc/eps-basic https://stock.noler.com/us/stock/eidos-therapeutics-inc/extinguishment-of-debt-amount https://stock.noler.com/us/stock/eidos-therapeutics-inc/fair-value-assets-level-1-to-level-2-transfers-amount https://stock.noler.com/us/stock/eidos-therapeutics-inc/fair-value-assets-level-2-to-level-1-transfers-amount https://stock.noler.com/us/stock/eidos-therapeutics-inc/fair-value-liabilities-level-1-to-level-2-transfers-amount https://stock.noler.com/us/stock/eidos-therapeutics-inc/fair-value-liabilities-level-2-to-level-1-transfers-amount https://stock.noler.com/us/stock/eidos-therapeutics-inc/fair-value-measurement-with-unobservable-inputs-reconciliation-liability-transfers-into-level https://stock.noler.com/us/stock/eidos-therapeutics-inc/fair-value-measurement-with-unobservable-inputs-reconciliation-liability-transfers-out-of-level https://stock.noler.com/us/stock/eidos-therapeutics-inc/financial-liabilities-fair-value-disclosure https://stock.noler.com/us/stock/eidos-therapeutics-inc/financing-cash-flow https://stock.noler.com/us/stock/eidos-therapeutics-inc/form-d-stocks https://stock.noler.com/us/stock/eidos-therapeutics-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/eidos-therapeutics-inc/gain-loss-on-termination-of-lease https://stock.noler.com/us/stock/eidos-therapeutics-inc/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/eidos-therapeutics-inc/general-and-administrative-expense https://stock.noler.com/us/stock/eidos-therapeutics-inc/impairment-of-long-lived-assets-held-for-use https://stock.noler.com/us/stock/eidos-therapeutics-inc/income-tax https://stock.noler.com/us/stock/eidos-therapeutics-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/eidos-therapeutics-inc/increase-decrease-in-accrued-liabilities-and-other-operating-liabilities https://stock.noler.com/us/stock/eidos-therapeutics-inc/increase-decrease-in-due-from-related-parties-current https://stock.noler.com/us/stock/eidos-therapeutics-inc/increase-decrease-in-due-to-related-parties-current https://stock.noler.com/us/stock/eidos-therapeutics-inc/increase-decrease-in-other-operating-assets https://stock.noler.com/us/stock/eidos-therapeutics-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/eidos-therapeutics-inc/incremental-common-shares-attributable-to-equity-unit-purchase-agreements https://stock.noler.com/us/stock/eidos-therapeutics-inc/incremental-common-shares-attributable-to-share-based-payment-arrangements https://stock.noler.com/us/stock/eidos-therapeutics-inc/insider-transactions-preferred https://stock.noler.com/us/stock/eidos-therapeutics-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/eidos-therapeutics-inc/insider-transactions-stock-units https://stock.noler.com/us/stock/eidos-therapeutics-inc/insider-transactions-warrants https://stock.noler.com/us/stock/eidos-therapeutics-inc/interest-expense https://stock.noler.com/us/stock/eidos-therapeutics-inc/interest-paid-net https://stock.noler.com/us/stock/eidos-therapeutics-inc/investing-cash-flow https://stock.noler.com/us/stock/eidos-therapeutics-inc/issuance-of-stock-and-warrants-for-services-or-claims https://stock.noler.com/us/stock/eidos-therapeutics-inc/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/eidos-therapeutics-inc/level-3-asset-transfers-into-level https://stock.noler.com/us/stock/eidos-therapeutics-inc/level-3-asset-transfers-out-of-level https://stock.noler.com/us/stock/eidos-therapeutics-inc/long-term-debt https://stock.noler.com/us/stock/eidos-therapeutics-inc/net-change-in-cash https://stock.noler.com/us/stock/eidos-therapeutics-inc/net-income https://stock.noler.com/us/stock/eidos-therapeutics-inc/net-income-loss-attributable-to-parent-diluted https://stock.noler.com/us/stock/eidos-therapeutics-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/eidos-therapeutics-inc/number-of-operating-segments https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-cash-flow https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-expenses https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-income https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-assets https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-expense https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-liability https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-liability-current https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-2 https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-after-year-five https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-leases-rent-expense-net https://stock.noler.com/us/stock/eidos-therapeutics-inc/operating-loss-carryforwards https://stock.noler.com/us/stock/eidos-therapeutics-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/eidos-therapeutics-inc/other-noncurrent-assets https://stock.noler.com/us/stock/eidos-therapeutics-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/eidos-therapeutics-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/eidos-therapeutics-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/eidos-therapeutics-inc/payments-of-financing-costs https://stock.noler.com/us/stock/eidos-therapeutics-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/eidos-therapeutics-inc/preferred-shares-facts https://stock.noler.com/us/stock/eidos-therapeutics-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/eidos-therapeutics-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/eidos-therapeutics-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/eidos-therapeutics-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/eidos-therapeutics-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/eidos-therapeutics-inc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/eidos-therapeutics-inc/proceeds-from-issuance-of-redeemable-convertible-preferred-stock https://stock.noler.com/us/stock/eidos-therapeutics-inc/proceeds-from-notes-payable https://stock.noler.com/us/stock/eidos-therapeutics-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/eidos-therapeutics-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/eidos-therapeutics-inc/proceeds-from-stock-plans https://stock.noler.com/us/stock/eidos-therapeutics-inc/profit-loss https://stock.noler.com/us/stock/eidos-therapeutics-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/eidos-therapeutics-inc/property-plant-equipment https://stock.noler.com/us/stock/eidos-therapeutics-inc/public-float https://stock.noler.com/us/stock/eidos-therapeutics-inc/redeemable-noncontrolling-interest-equity-preferred-carrying-amount https://stock.noler.com/us/stock/eidos-therapeutics-inc/related-party-transaction-selling-general-and-administrative-expenses-from-transactions-with-related-party https://stock.noler.com/us/stock/eidos-therapeutics-inc/research-and-development https://stock.noler.com/us/stock/eidos-therapeutics-inc/retained-earnings https://stock.noler.com/us/stock/eidos-therapeutics-inc/revenue https://stock.noler.com/us/stock/eidos-therapeutics-inc/right-of-use-asset-obtained-in-exchange-for-operating-lease-liability https://stock.noler.com/us/stock/eidos-therapeutics-inc/shareholders-equity https://stock.noler.com/us/stock/eidos-therapeutics-inc/shares-authorized https://stock.noler.com/us/stock/eidos-therapeutics-inc/shares-issued https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-award-fair-value-assumptions-expected-dividend-payments https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-award-number-of-additional-shares-authorized https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-award-number-of-shares-available-for-grant https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-based-compensation https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-issued-shares-issued-value-espp https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-issued-shares-issued-value-issued-for-services https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-vested-and-expected-to-vest-exercisable-aggregate-intrinsic-value https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-options-vested-in-period-fair-value https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-repurchase-program-remaining-number-of-shares-authorized-to-be-repurchased https://stock.noler.com/us/stock/eidos-therapeutics-inc/stock-split-ratio https://stock.noler.com/us/stock/eidos-therapeutics-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/eidos-therapeutics-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/eidos-therapeutics-inc/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/eidos-therapeutics-inc/tax-rate-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/eidos-therapeutics-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/eidos-therapeutics-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/eidos-therapeutics-inc/tax-rate-reconciliation-tax-credits-research https://stock.noler.com/us/stock/eidos-therapeutics-inc/temporary-equity-carrying-amount-attributable-to-parent https://stock.noler.com/us/stock/eidos-therapeutics-inc/temporary-equity-liquidation-preference https://stock.noler.com/us/stock/eidos-therapeutics-inc/temporary-equity-par-or-stated-value-per-share https://stock.noler.com/us/stock/eidos-therapeutics-inc/temporary-equity-shares-authorized https://stock.noler.com/us/stock/eidos-therapeutics-inc/temporary-equity-shares-issued https://stock.noler.com/us/stock/eidos-therapeutics-inc/temporary-equity-shares-outstanding https://stock.noler.com/us/stock/eidos-therapeutics-inc/total-assets https://stock.noler.com/us/stock/eidos-therapeutics-inc/total-liabilities https://stock.noler.com/us/stock/eidos-therapeutics-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/eidos-therapeutics-inc/total-long-term-debt https://stock.noler.com/us/stock/eidos-therapeutics-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/eidos-therapeutics-inc/utb-increase-from-current-year-positions https://stock.noler.com/us/stock/eidos-therapeutics-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/eidos-therapeutics-inc/weighted-average-number-of-share-outstanding-basic-and-diluted https://stock.noler.com/us/stock/eidos-therapeutics-inc/weighted-average-number-of-shares-common-stock-subject-to-repurchase-or-cancellation https://stock.noler.com/us/stock/eidos-therapeutics-inc/weighted-average-number-of-shares-issued-basic